Profile of Tofacitinib Citrate and Its Potential in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
January 2016
in “
Drug design, development and therapy
”
TLDR Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
Tofacitinib citrate, an oral JAK inhibitor, showed promise in treating moderate-to-severe chronic plaque psoriasis by interrupting intracellular signaling and suppressing immune cell activation. Clinical trials demonstrated that a 10 mg bid dose of tofacitinib was as effective as etanercept 50 mg administered subcutaneously twice weekly. However, safety concerns remained for doses beyond 5 mg bid. The review also suggested potential future applications of tofacitinib in treating other skin diseases, such as alopecia areata and vitiligo.
